agilon health's stock has surged 538% in six months to a 52-week high of $117.62, but analysts highlight three risks. Its customer base fell to 426,000, averaging a 3.1% annual decline over two years, signaling competitive or saturation pressures. Revenue growth is expected to stall in the next 12 months, a sharp slowdown from 34.1% annualized growth over the past five years. The company has burned cash over the long term, with a five-year average free cash flow margin of negative 2.8%, meaning it lost $2.76 for every $100 in revenue. The stock trades at 97.9 times forward EV-to-EBITDA, and analysts suggest a digital advertising pick as a better alternative.
agilon health IncCustomer base declining 3.1% annually over two years signals competitive or saturation pressures.